Menu

U Power Limited UCAR

Full chart Compare
Set alert

Price alert · UCAR

All alert types
2.93 USD -0.02 (-0.68%)

Nov 12, 2026, 3:57 PM EST

2.55 Day range 2.95
2.34 52-week range 427.40
YTD
-99.04%
1 year
-99.33%

Discussion (475)

Sign in to join the discussion

dan rd UCAR 2 years ago #451

Who shorty just for a penny spike ?

dan rd UCAR 2 years ago #452

Hey shorty I’ll give u penny how’s that lol

dan rd UCAR 2 years ago #453

$0.45 cents end of the day ?

dan rd UCAR 2 years ago #454

Its time go to the moon ??

VICKY HANUKA UCAR 3 years ago #459

"During this quarter, we executed an agreement with United States Air Force Academy ("USAFA") for an initial amount of US$7.3million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. Our partnership with USAFA and the recent agreement execution will enable us to advance this program towards an Investigational New Drug ("IND")," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "Additionally, securing US patent coverage through at least 2039 for ATI-1501, our Metronidazole formulation, is a significant milestone leading up to the anticipated FDA Prescription Drug User Fee ("PDUFA") date on September 23, 2023. We look forward to receiving milestone payments and royalties from our partner, Saptalis Pharmaceuticals LLC ("Saptalis"), in the coming quarters based on their submission and commercialization plans. These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."